Seagen and Nurix Therapeutics are partnering to develop a new class of cancer drugs, dubbed degrader antibody conjugates (DACs), which combine protein degraders with antibody drug conjugates. Under the multi-year agreement, Seagen will handle the creation and development of the DACs, and could pay out up to $3.4 billion to Nurix if certain milestones are hit. Nurix could also receive royalties in case of sales from approved products and has the option to share in US commercialisation of two products.
Stop blaming maintainers for open source risks
Open source leaders are pushing for permanent government financing to maintain open source projects. They argue that as government oversight is vital to the national
